Merck KGaA operates in three key segments: healthcare, life science, and electronics. Over the past decade, strategic acquisitions and divestitures have strengthened its position across these industries, broadened its exposure to end markets with stronger long-term growth potential, and supported its competitive advantages.
Merck’s life science segment is strategically positioned to capitalize on robust industry growth, driven by pharmaceutical companies’ increased R&D investments.
Merck’s healthcare segment faces significant sales declines due to patent expirations, lack of patent protection, and advancements in biologics manufacturing.
|
Metric
|
MKKGY
|
BIIB
|
DHR
|
|---|---|---|---|
Price/Earnings (Normalized) | 16.00 | 15.95 | 26.08 |
Price/Book Value | 1.90 | 1.75 | 2.83 |
Price/Sales | 2.65 | 3.29 | 6.00 |
Price/Cash Flow | 12.33 | 10.38 | 21.01 |
|
Metric
|
MKKGY
|
BIIB
|
DHR
|
|---|---|---|---|
Quick Ratio | 0.99 | 0.94 | 1.03 |
Current Ratio | 1.69 | 1.87 | 1.65 |
Interest Coverage | 7.22 | 4.09 | 16.95 |
|
Metric
|
MKKGY
|
BIIB
|
DHR
|
|---|---|---|---|
Return on Assets (Normalized) | 4.75% | 6.96% | 5.34% |
Return on Equity (Normalized) | 8.32% | 11.28% | 8.59% |
Return on Invested Capital (Normalized) | 6.65% | 8.68% | 6.45% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Teva Pharmaceutical Industries Ltd
TEVA
| LOCK|m%<>c<y | LOCK|brh# | $46B | |||
| Haleon PLC ADR
HLN
| LOCK|%rPmwr | LOCK|^@ | $38B | |||
| Zoetis Inc Class A
ZTS
| LOCK|#TKsZrVK | LOCK|$>P | $29B | |||
| Viatris Inc
VTRS
| LOCK|%%Bwpp | LOCK|v&? | $20B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|xh | LOCK|kGr | $11B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|^>$x?$ | LOCK|Y^C | $10B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|b@gn%k | LOCK|%y | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|w!ZN#C# | LOCK|h^>lL | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|!y%&C% | LOCK|@& | $2B |
United States